Elevated levels of circulating thyroid hormone do not cause the medical sequelae of hyperthyroidism

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 71, Issue , 2016, Pages 1-6

  Kelly, Tammas ^a,b   Denmark, Lawrence ^b   Lieberman, Daniel Z ^a  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b The Depression and Bipolar Clinic of Colorado   (United States)

Author keywords

Bipolar; Etiology; Hyperthyroidism; Iatrogenic; Morbidity; Sequelae

Indexed keywords

CALCIUM; THYROID HORMONE;

AGE; ATRIAL FIBRILLATION; BONE DENSITY; BONE TURNOVER; CALCIUM INTAKE; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; DIFFERENTIATED THYROID CANCER; DRUG EFFECT; GRAVES DISEASE; HIGH DOSE THYROID TREATMENT; HORMONAL THERAPY; HUMAN; HYPERTENSION; HYPERTHYROIDISM; MORBIDITY; MULTICENTER STUDY (TOPIC); OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; THYROID CARCINOMA; THYROIDITIS; BIBLIOGRAPHIC DATABASE; BLOOD; COMPLICATION; METABOLISM; STATISTICS AND NUMERICAL DATA; THYROID GLAND;

DATABASES, BIBLIOGRAPHIC; HUMANS; HYPERTHYROIDISM; OSTEOPOROSIS; THYROID GLAND; THYROID HORMONES;

EID: 84974782320     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2016.06.001     Document Type: Review

References (47)

1. Abonowara A., Quraishi A., Sapp J.L., Alqambar M.H., Saric A., O'Connell C.M., Rajaraman M.M., Hart R.D., Imran S.A. Prevalence of atrial fibrillation in patients taking TSH suppression therapy for management of thyroid cancer. Clin. Investig. Med. 2012, 35:E152-E156.
2. Bahn R.S., Burch H.B., Cooper D.S., Garber J.R., Greenlee M.C., Klein I., Laurberg P., McDougall I.R., Montori V.M., Rivkees S.A. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 2011, 21:593-646.
3. Bauer M.S., Whybrow P.C. Rapid cycling bipolar affective disorder: II. Treatment of refractory rapid cycling with high-dose levothyroxine: a preliminary study. Arch. Gen. Psychiatry 1990, 47:435.
4. Bauer M., Whybrow P.C. Thyroid hormone, neural tissue and mood modulation. World J. Biol. Psychiatry 2001, 2:59-69.
5. Bauer M., Hellweg R., Gräf K.-J., Baumgartner A. Treatment of refractory depression with high-dose thyroxine. Neuropsychopharmacology 1998, 18:444-455.
6. Bauer M., Adli M., Bschor T., Heinz A., Rasgon N., Frye M., Grunze H., Kupka R., Whybrow P. Clinical applications of levothyroxine in refractory mood disorders. Clin. Appl. Bipolar Disord. 2003, 2:49-56.
7. Bauer M., London E., Rasgon N., Berman S., Frye M., Altshuler L., Mandelkern M., Bramen J., Voytek B., Woods R. Supraphysiological doses of levothyroxine alter regional cerebral metabolism and improve mood in bipolar depression. Mol. Psychiatry 2005, 10:456-469.
8. Bauer M., Berman S., Stamm T., Plotkin M., Adli M., Pilhatsch M., London E., Hellemann G., Whybrow P., Schlagenhauf F. Levothyroxine effects on depressive symptoms and limbic glucose metabolism in bipolar disorder: a randomized, placebo-controlled positron emission tomography study. Mol. Psychiatry 2015.
9. Belaya Z.E., Melnichenko G.A., Rozhinskaya L.Y., Fadeev V.V., Alekseeva T.M., Dorofeeva O.K., Sasonova N.I., Kolesnikova G.S. Subclinical Hyperthyroidism of Variable Etiology and its Influence on Bone in Postmenopausal Women. HORMONES-ATHENS-6, 62 2007.
10. Biondi B. Mechanisms in endocrinology: heart failure and thyroid dysfunction. European Journal of Endocrinology 2012, 167:609-618.
11. Biondi B., Kahaly G.J. Cardiovascular involvement in patients with different causes of hyperthyroidism. Nat. Rev. Endocrinol. 2010, 6:431-443.
12. Brandt F., Green A., Hegedüs L., Brix T.H. A critical review and meta-analysis of the association between overt hyperthyroidism and mortality. Eur. J. Endocrinol. 2011, 165:491-497.
13. Cooper D.S., Doherty G.M., Haugen B.R., Kloos R.T., Lee S.L., Mandel S.J., Mazzaferri E.L., McIver B., Pacini F., Schlumberger M. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2009, 19:1167-1214.
14. Crismon M.L., Argo T.R., Bendele S.D., Suppes T. Texas Medication Algorithm Project Procedural Manual, Bipolar Disorder Algorithms 2007, Texas Department of State Health Services.
15. Drvota V., Janson A., Norman C., Sylven C., Haggblad J., Bronnegard M., Marcus C. Evidence for the presence of functional thyrotropin receptor in cardiac muscle. Biochem. Biophys. Res. Commun. 1995, 211:426-431.
16. Eftekhari M., Asadollahi A., Beiki D., Izadyar S., Gholamrezanezhad A., Assadi M., Fard-Esfahani A., Fallahi B., Takavar A., Saghari M. The long term effect of levothyroxine on bone mineral density in patients with well differentiated thyroid carcinoma after treatment. Hell. J. Nucl. Med. 2008, 11:160-163.
17. Fadel B.M., Ellahham S., Lindsay J., Ringel M.D., Wartofsky L., Burman K.D. Hyperthyroid heart disease. Clin. Cardiol. 2000, 23:402-408.
18. Fazio S., Palmieri E.A., Lombardi G., Biondi B. Effects of thyroid hormone on the cardiovascular system. Recent Prog. Horm. Res. 2004, 59:31-50.
19. Gershengorn M.C., Neumann S. Update in TSH receptor agonists and antagonists. J. Clin. Endocrinol. Metab. 2012, 97:4287-4292.
20. Go A.S., Hylek E.M., Phillips K.A., Chang Y., Henault L.E., Selby J.V., Singer D.E. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001, 285:2370-2375.
21. Gyulai L., Jaggi J., Bauer M.S., Younkin S., Rubin L., Attie M., Whybrow P.C. Bone mineral density and l-thyroxine treatment in rapidly cycling bipolar disorder. Biol. Psychiatry 1997, 41:503-506.
22. Gyulai L., Bauer M., Garcia-Espana F., Hierholzer J., Baumgartner A., Berghöfer A., Whybrow P.C. Bone mineral density in pre-and post-menopausal women with affective disorder treated with long-term l-thyroxine augmentation. J. Affect. Disord. 2001, 66:185-191.
23. Heemstra K., Hamdy N., Romijn J., Smit J. The effects of thyrotropin-suppressive therapy on bone metabolism in patients with well-differentiated thyroid carcinoma. Thyroid 2006, 16:583-591.
24. Hesselink E.N.K., Hesselink M.S.K., de Bock G.H., Gansevoort R.T., Bakker S.J., Vredeveld E.J., van der Horst-Schrivers A.N., van der Horst I.C., Kamphuisen P.W., Plukker J.T. Long-term cardiovascular mortality in patients with differentiated thyroid carcinoma: an observational study. J. Clin. Oncol. 2013, (2013.2049. 1043).
25. Higashiguchi M., Onoda T., Turin T.C., Sakata K. Calcium intake and associated factors in a general Japanese population: baseline data of NIPPON DATA80/90 and the National Nutrition Survey. J. Epidemiol. Jpn. Epidemiol. Assoc. 2009, 20:S549-S556.
26. Hirschfeld R. Guideline watch: practice guideline for the treatment of patients with bipolar disorder, APA Practice Guidelines. Am. Psychiatr. Assoc. 2010.
27. Jodar E., Lopez M.B., Garcia L., Rigopoulou D., Martinez G., Hawkins F. Bone changes in pre-and postmenopausal women with thyroid cancer on levothyroxine therapy: evolution of axial and appendicular bone mass. Osteoporos. Int. 1998, 8:311-316.
28. Jonklaas J., Sarlis N.J., Litofsky D., Ain K.B., Bigos S.T., Brierley J.D., Cooper D.S., Haugen B.R., Ladenson P.W., Magner J. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 2006, 16:1229-1242.
29. Kelly T. A favorable risk-benefit analysis of high dose thyroid for treatment of bipolar disorders with regard to osteoporosis. J. Affect. Disord. 2014.
30. Kelly T. An examination of myth: a favorable cardiovascular risk-benefit analysis of high-dose thyroid for affective disorders. J. Affect. Disord. 2015, 177:49-58.
31. Klein I., Danzi S. Thyroid disease and the heart. Circulation 2007, 116:1725-1735.
32. Kung A., Yeung S. Prevention of bone loss induced by thyroxine suppressive therapy in postmenopausal women: the effect of calcium and calcitonin. J. Clin. Endocrinol. Metab. 1996, 81:1232-1236.
33. Lakatos P. Thyroid hormones: beneficial or deleterious for bone?. Calcif. Tissue Int. 2003, 73:205-209.
34. Laurberg P., Wallin G., Tallstedt L., Abraham-Nordling M., Lundell G., Tørring O. TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur. J. Endocrinol. 2008, 158:69-75.
35. Links T., Van Tol K., Jager P., Plukker J.T.M., Piers D., Boezen H., Dullaart R., de Vries E., Sluiter W. Life expectancy in differentiated thyroid cancer: a novel approach to survival analysis. Endocr. Relat. Cancer 2005, 12:273-280.
36. Ortiz-Domínguez A., Hernández M.E., Berlanga C., Gutiérrez-Mora D., Moreno J., Heinze G., Pavón L. Immune variations in bipolar disorder: phasic differences. Bipolar Disord. 2007, 9:596-602.
37. Perros P., Boelaert K., Colley S., Evans C., Evans R.M., Gerrard B., Gilbert J., Harrison B., Johnson S.J., Giles T.E. Guidelines for the management of thyroid cancer. Clin. Endocrinol. 2014, 81:1-122.
38. Quan M.L., Pasieka J.L., Rorstad O. Bone mineral density in well-differentiated thyroid cancer patients treated with suppressive thyroxine: a systematic overview of the literature. J. Surg. Oncol. 2002, 79:62-69. (discussion 69-70).
39. Ricken R., Bermpohl F., Schlattmann P., Bschor T., Adli M., Mönter N., Bauer M. Long-term treatment with supraphysiological doses of thyroid hormone in affective disorders-effects on bone mineral density. J. Affect. Disord. 2012, 136:e89-e94.
40. Sachs G.S., Printz D.J., Kahn D.A., Carpenter D., Docherty J.P. The expert consensus guideline series: medication treatment of bipolar disorder. Postgrad. Med. 2000, 1:1-104.
41. Sawin C.T., Geller A., Wolf P.A., Belanger A.J., Baker E., Bacharach P., Wilson P., Benjamin E.J., D'Agostino R.B. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N. Engl. J. Med. 1994, 331:1249-1252.
42. Sugitani I., Fujimoto Y. Effect of postoperative thyrotropin suppressive therapy on bone mineral density in patients with papillary thyroid carcinoma: a prospective controlled study. Surgery 2011, 150:1250-1257.
43. Toft A.D. Subclinical hyperthyroidism. N. Engl. J. Med. 2001, 345:512-516.
44. Topliss D.J., Eastman C.J. 5: diagnosis and management of hyperthyroidism and hypothyroidism. Med. J. Aust. 2004, 180:186-194.
45. Vallabhajosula S., Radhi S., Cevik C., Alalawi R., Raj R., Nugent K. Hyperthyroidism and pulmonary hypertension: an important association. Am. J. Med. Sci. 2011, 342:507-512.
46. Wall J.R., Lahooti H. Pathogenesis of thyroid eye disease-does autoimmunity against the TSH receptor explain all cases?. Endokrynol. Pol. 2010, 61:222-227.
47. Yatham L.N., Kennedy S.H., Parikh S.V., Schaffer A., Beaulieu S., Alda M., O'Donovan C., MacQueen G., McIntyre R.S., Sharma V. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 2013, 15:1-44.